Publications by authors named "Rong-Hua Xie"
Article Synopsis
- Scientists studied a disease called ankylosing spondylitis (AS) that happens when the immune system attacks the body.
- They found that a special type of change in proteins, called carboxyethylation, helps create new pieces (neoantigens) that confuse the immune system.
- When these changes happen, they can lead to problems like inflammation and damage to bones, shown in experiments with mice.
Meplazumab, a humanized CD147 antibody, has shown favourable safety and efficacy in our previous clinical studies. In DEFLECT (NCT04586153), 167 patients with severe COVID-19 were enroled and randomized to receive three dosages of meplazumab and a placebo. Meplazumab at 0.
View Article and Find Full Text PDFRecent evidence suggests that CD147 serves as a novel receptor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Blocking CD147 via anti-CD147 antibody could suppress the in vitro SARS-CoV-2 replication. Meplazumab is a humanized anti-CD147 IgG monoclonal antibody, which may effectively prevent SARS-CoV-2 infection in coronavirus disease 2019 (COVID-19) patients.
View Article and Find Full Text PDFArticle Synopsis
- The study compared clinical features of interstitial pneumonia with autoimmune features (IPAF) and connective tissue disease interstitial lung disease (CTD-ILD), finding significant differences in symptoms and lung function metrics.
- Out of 412 patients studied, it was observed that all IPAF patients were autoantibody positive, while those with CTD-ILD experienced more extrapulmonary symptoms.
- IPAF patients showed better lung function (higher FVC and diffusing capacity) and improved lung function after immunosuppressive treatment, suggesting the need for early intervention similar to that for CTD-ILD.